featured
Prasinezumab for Early-Stage Parkinson's Disease
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The New England Journal of Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Trial of Prasinezumab in Early-Stage Parkinson's Disease
N. Engl. J. Med 2022 Aug 04;387(5)421-432, G Pagano, KI Taylor, J Anzures-Cabrera, M Marchesi, T Simuni, K Marek, RB Postuma, N Pavese, F Stocchi, JP Azulay, B Mollenhauer, L López-Manzanares, DS Russell, JT Boyd, AP Nicholas, MR Luquin, RA Hauser, T Gasser, W Poewe, B Ricci, A Boulay, A Vogt, FG Boess, J Dukart, G D'Urso, R Finch, S Zanigni, A Monnet, N Pross, A Hahn, H Svoboda, M Britschgi, F Lipsmeier, E Volkova-Volkmar, M Lindemann, S Dziadek, Š Holiga, D Rukina, T Kustermann, GA Kerchner, P Fontoura, D Umbricht, R Doody, T Nikolcheva, A BonniFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.